Method of Inhibiting Mucin Secretion
A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin.
1 . A method of inhibiting mucus secretion in an individual comprising administering an effective amount of a composition comprising guaifenesin.
2 . The method as claimed in claim 1 , wherein the composition comprises from approximately 600 mg-1200 mg of guaifenesin.
3 . The method as claimed in claim 2 , wherein the composition comprises approximately 600 mg of guaifenesin.
4 . The method as claimed in claim 2 , wherein the composition comprises approximately 1200 mg of guaifenesin.
5 . The method as claimed in claim 1 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a tablet.
6 . The method as claimed in claim 1 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a powder.
7 . The method as claimed in claim 1 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a capsule.
8 . The method as claimed in claim 1 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a liquid.
9 . The method as claimed in claim 1 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a liquigel.
10 . The method as claimed in claim 1 , wherein the mucus secretion is produced in the upper respiratory tract of an individual.
11 . The method as claimed in claim 1 , wherein the composition further comprises one or more active agents.
12 . The method as claimed in claim 11 , wherein the one or more active agents are selected from the group consisting of an antitussive, a decongestant, and an antihistamine.
13 . The method as claimed in claim 12 , wherein the antitussive comprises dextromethorphan hydrobromide.
14 . The method as claimed in claim 12 , wherein the decongestant is selected from the group consisting of phenylephrine hydrochloride, pseudoephedrine hydrochloride and ephedrine.
15 . The method as claimed in claim 12 , wherein the antihistamine is selected from the group consisting of chlorpheniramine maleate, brompheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, phenyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, clemastine fumerate, and fexofenadine, or a combination thereof.
16 . The method as claimed in claim 1 , wherein the composition comprises an immediate release portion and a sustained release portion, such that the inhibition of mucus secretion is therapeutically achieved for a period of approximately 12 hours.
17 . A method of treating an individual having a disease or condition characterized by increased mucin secretion with an effective amount of a composition comprising guaifenesin.
18 . The method as claimed in claim 17 , wherein the composition comprises from approximately 600 mg-1200 mg of guaifenesin.
19 . The method as claimed in claim 18 , wherein the composition comprises approximately 600 mg of guaifenesin.
20 . The method as claimed in claim 18 , wherein the composition comprises approximately 1200 mg of guaifenesin.
21 . The method as claimed in claim 17 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a tablet.
22 . The method as claimed in claim 17 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a powder.
23 . The method as claimed in claim 17 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a capsule.
24 . The method as claimed in claim 17 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a liquid.
25 . The method as claimed in claim 17 , wherein administering an effective amount of a composition comprising guaifenesin comprises administering the composition as a liquigel.
26 . The method as claimed in claim 17 , wherein the mucus secretion is produced in the upper respiratory tract of an individual.
27 . The method as claimed in claim 17 , wherein the composition further comprises one or more active agents.
28 . The method as claimed in claim 27 , wherein the one or more active agents are selected from the group consisting of an antitussive, a decongestant, and an antihistamine.
29 . The method as claimed in claim 28 , wherein the antitussive comprises dextromethorphan hydrobromide.
30 . The method as claimed in claim 28 , wherein the decongestant is selected from the group consisting of phenylephrine hydrochloride, pseudoephedrine hydrochloride and ephedrine.
31 . The method as claimed in claim 28 , wherein the antihistamine is selected from the group consisting of chlorpheniramine maleate, brompheniramine maleate, phenindamine tartrate, pyrilamine maleate, doxylamine succinate, phenyltoloxamine citrate, diphenhydramine hydrochloride, promethazine, clemastine fumerate, and fexofenadine, or a combination thereof.
32 . The method as claimed in claim 17 , wherein the composition comprises an immediate release portion and a sustained release portion, such that the inhibition of mucus secretion is therapeutically achieved for a period of approximately 12 hours.